Kymera TherapeuticsNASDAQ: KYMR

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Justine Koenigsberg - VP, IR Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - CFO Conference Call Participants Marc Frahm - TD Cowen Kalpit Patel - B. Riley Alexei Siniakov - Truist Securities Brad Canino - Stifel Nicolaus Gospel Enyindah-Asonye - Morgan Stanley Kelly Shi - Jefferies Jeff Jones - Oppenheimer Eric Joseph - J.P.

Kymera reports a narrower-than-expected loss in the third quarter. The company expects the current cash balance to provide a runway into mid-2027.

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025

KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases

KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.

KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases

Kymera Therapeutics' innovative TPD technology degrades disease-causing proteins, with promising candidates like KT-474 and KT-621 targeting large TAMs in immunology and oncology. The company's approach leverages the body's proteasome system to degrade harmful proteins. This could lead to safer and less invasive treatments. Kymera's cash runway of approximately 4.9 years is expected to support the advancement of its pipeline until 2027.

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease